One Class C Manufacturing Licence: Heyuan Biopharma Closes the CGT CDMO Loop as Export Controls Push the Business Inward

On the evening of 28 October 2026, Heyuan Biopharma (688238.SH) reported Q3 revenue of RMB 84.7M (+40.04%) with losses narrowing by RMB 12.9M year on year; nine-month new CDMO bookings exceeded RMB 230M, and the company has helped clients secure 78 China-US IND approvals to date. The milestone sits in licensing: in July 2026 the company obtained a Class C Drug Manufacturing Licence from the Shanghai medical products regulator, becoming one of very few domestic providers with both scaled CGT capacity and licensed commercial contract manufacturing. With Announcement No. 48 proposing to ban the export of CGT process platforms, this has become a purely domestic-closed-loop business.

On the evening of 28 October 2026, cell and gene therapy (CGT) CDMO Heyuan Biopharma (688238.SH) reported its Q3 results. Q3 revenue was RMB 84.73M, up 40.04% year on year; net loss was RMB 44.69M, narrowing by RMB 12.85M from a year earlier. Nine-month revenue was RMB 207M (+14.50%): CGT CRO services RMB 72.77M (+17.38%), CGT CDMO services RMB 104.29M (+7.85%), regenerative-medicine services RMB 3.75M (+63.36%).

But the most important disclosure is not revenue — it is the licence the company re-emphasised on 28 October: a Class C Drug Manufacturing Licence issued by the Shanghai medical products regulator in July 2026. With it, Heyuan is licensed to conduct commercial-scale contract manufacturing of CGT products, making it one of very few domestic providers with both ample scaled capacity and the commercial manufacturing licence — completing a closed loop from early research and process development through to commercial production.

The Class C licence: a threshold asset for CGT CDMOs

To see why the licence matters, look at the industry's structure. Unlike small molecules or conventional biologics, CGT production systems — viral vectors, cell-therapy suites — offer almost no off-the-shelf generic capacity, and regulators scrutinise contract-manufacturing licences with exceptional rigour. Most Chinese CGT biotechs historically built their own lines precisely because no licensed commercial CDMO existed to take the work; those in-house lines, in turn, are capital-heavy and chronically underutilised.

Hence the scarcity value of the Class C licence: it converts 'can we legally hand over commercial manufacturing' from a theoretical question into a licence question. Heyuan has helped clients secure 78 multi-country IND approvals to date (17 of them from the US FDA), including 15 in the first three quarters of 2026 (3 from FDA). IND count is the water level at the front of the CGT CDMO funnel; licensed commercial capacity is the width of its outlet. Only with both does the funnel actually work.

The company's 'AI+CGT' build-out is also worth noting: data integration across research, GMP production, quality control and programme management forms a closed loop of intelligent design, model building, algorithm validation and big-data feedback, compressing vector-screening and process-development timelines. This aligns with the AI4S×CXO thread we have tracked (OpenAI's acquisition of Orchestra Bio, WuXi AppTec's first mention of AI-driven client demand in a periodic report) — and CGT, being the most process-complex modality, may be the biggest beneficiary of AI-enabled outsourcing.

After Announcement No. 48: CGT outsourcing becomes a domestic closed loop

In October, China's Ministry of Commerce and Ministry of Science and Technology issued Announcement No. 48 (draft), placing five biopharmaceutical technologies under export control, with CGT process platforms proposed for the prohibited-export list. When we analysed it, the impact on large CXOs was buffered by business-structure mismatch: WuXi AppTec had sold its CGT unit to Altaris and its TIDES business is peptide-led.

For a purely domestic CGT CDMO like Heyuan, the causality runs the other way: export controls close off the 'Chinese process platform going abroad' route and block certain offshore-CDMO participation in Chinese CGT programmes, so domestic biotech outsourcing demand has nowhere to land except domestic capacity. The scarcity of the Class C licence is therefore amplified by policy — a licensed player faces a better competitive field in a forced domestic loop than it did before the announcement.

The other side of the closed loop is a capped ceiling: a domestic-only CGT CDMO grows entirely with domestic biotech financing and pipeline progress. With China's out-licensing total passing USD 130B in 2026 and primary-market sentiment clearly recovering, the tailwind is real today; but if the financing cycle turns, a business with no export option feels it first.

Editor's view: the path out of losses, and the CGT commercialisation time lag

Heyuan remains loss-making (Q3 loss of RMB 44.7M, narrowing), and the route to breakeven is a race between two clocks: converting new bookings (over RMB 230M in nine months) into revenue — Q3's 40% revenue growth signals acceleration — and landing the first commercial batches. CDMO revenue grew only 7.85% year on year, which the company attributes to the mix of in-execution orders and programme timing; in essence the existing book remains clinical-stage, with commercial batches yet to scale.

At the industry level, CGT outsourcing is a classic triple-barrier business — licence, capacity, experience — with long payback but durable structure. What this quarter's report signals is that the threshold asset (the Class C licence) is in hand and the front of the funnel (78 INDs) keeps filling; what remains is waiting for the first commercial batches to lift utilisation past breakeven. That time lag is a natural timer for observing the industrialisation of China's CGT sector.